BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31888963)

  • 1. Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes.
    Roberts JT; Patel KR; Barb AW
    Mol Cell Proteomics; 2020 Feb; 19(2):362-374. PubMed ID: 31888963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability.
    Patel KR; Nott JD; Barb AW
    Mol Cell Proteomics; 2019 Nov; 18(11):2178-2190. PubMed ID: 31467031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restricted processing of CD16a/Fc γ receptor IIIa
    Patel KR; Roberts JT; Subedi GP; Barb AW
    J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD16a with oligomannose-type
    Subedi GP; Barb AW
    J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes.
    Patel KR; Roberts JT; Barb AW
    Glycobiology; 2020 Jul; 30(7):427-432. PubMed ID: 31967297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a.
    Roberts JT; Barb AW
    J Biol Chem; 2018 Dec; 293(51):19899-19908. PubMed ID: 30361439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
    Kremer PG; Barb AW
    J Biol Chem; 2022 Sep; 298(9):102329. PubMed ID: 35921896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of
    Van Coillie J; Schulz MA; Bentlage AEH; de Haan N; Ye Z; Geerdes DM; van Esch WJE; Hafkenscheid L; Miller RL; Narimatsu Y; Vakhrushev SY; Yang Z; Vidarsson G; Clausen H
    Front Immunol; 2022; 13():987151. PubMed ID: 36189205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor.
    Subedi GP; Barb AW
    MAbs; 2016; 8(8):1512-1524. PubMed ID: 27492264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
    Falconer DJ; Subedi GP; Marcella AM; Barb AW
    ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells.
    Patel KR; Rodriguez Benavente MC; Lorenz WW; Mace EM; Barb AW
    J Biol Chem; 2021; 296():100183. PubMed ID: 33310702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms.
    Cambay F; Forest-Nault C; Dumoulin L; Seguin A; Henry O; Durocher Y; De Crescenzo G
    Mol Immunol; 2020 May; 121():144-158. PubMed ID: 32222585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
    Rodriguez Benavente MC; Hughes HB; Kremer PG; Subedi GP; Barb AW
    Immunology; 2023 Oct; 170(2):202-213. PubMed ID: 37218360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab.
    Hayes JM; Frostell A; Karlsson R; Müller S; Martín SM; Pauers M; Reuss F; Cosgrave EF; Anneren C; Davey GP; Rudd PM
    Mol Cell Proteomics; 2017 Oct; 16(10):1770-1788. PubMed ID: 28576848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antibody-binding Fc gamma receptor IIIa / CD16a is N-glycosylated with high occupancy at all five sites.
    Lampros EA; Kremer PG; Aguilar Díaz de León JS; Roberts ET; Rodriguez Benavente MC; Amster IJ; Barb AW
    Curr Res Immunol; 2022; 3():128-135. PubMed ID: 35712026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbohydrate-Polypeptide Contacts in the Antibody Receptor CD16A Identified through Solution NMR Spectroscopy.
    Subedi GP; Falconer DJ; Barb AW
    Biochemistry; 2017 Jun; 56(25):3174-3177. PubMed ID: 28613884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions.
    Hayes JM; Frostell A; Cosgrave EF; Struwe WB; Potter O; Davey GP; Karlsson R; Anneren C; Rudd PM
    J Proteome Res; 2014 Dec; 13(12):5471-85. PubMed ID: 25345863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
    Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D
    PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
    Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
    MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligomannose
    Fogarty CA; Fadda E
    J Phys Chem B; 2021 Mar; 125(10):2607-2616. PubMed ID: 33661628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.